Deuxième trimestre 2010 : AACR et ASCO
AACR - Annual meeting 2010 - April 17-21 2010 Washington - US
Prostate adenocarcinoma and intensive bone remodeling in a new prostate cancer IGR-CaP1 preclinical model derived from a human primary tumorNader AL NAKOUZI1, Paule OPOLON2, Olivia BAWA2, Stéphanie LERONDEL3, Alain LE PAPE3, Patrick GONIN2, Christophe MASSARD1, Karim FIZAZI1, Anne CHAUCHEREAU11INSERM U981- Institut Gustave Roussy, Villejuif,France; 2Institut Gustave Roussy, Villejuif, France; 3Imaging Department CIPA CNRS TAAM-UPS44, Orléans, France
Visualisez l'affiche
Involvement of cleaved p73 isoforms in anoïkisSamar Alsafadi, Sophie Tourpin, Gilles Vassal, Fabrice André and Jean Charles Ahomadegbe INSERM U981 “Biomarkers and new anticancer molecular strategies”, UPRESS EA3535 “Pharmacology and New Cancer Treatments”, Gustave Roussy Cancer Institute, Villejuif, France.
Visualisez l'afficheCirculating endothelial cell (CEC) measurement allows early prediction of outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line bevacizumab and chemotherapy. Findings from the FNCLCC ACCORD 13/0503 randomized phase IIValérie Boige (1), Jean Mendiboure (1), Antoine Adenis (2), Eveline Boucher (3), Jean-Yves Pierga (4), Eric François (5), Thierry Conroy (6), Jean-Pierre Pignon (1), Michel Ducreux (1), Françoise Farace (1), David Malka (1) .1 Institut Gustave Roussy, Villejuif; 2 Centre Oscar Lambret, Lille; 3 Centre Eugène Marquis, Rennes;
4 Institut Curie, Paris; 5 Centre Antoine Lacassagne, Nice; 6 Centre Alexis Vautrin, Vandoeuvre les Nancy.
Visualisez l'afficheChanges in signaling pathways induced by vandetanib in a human medullary thyroid carcinoma model as detected by Reverse Phase Protein Arrays.Sophie Broutin1, Fréderic Commo1, Leanne De Koning2, Caroline Hego2, Bérengère Marty2, Corinne Dupuy1, Anderson Joseph Ryan3, Martin Schlumberger1, Jean-Michel Bidart11Institut Gustave Roussy, Villejuif, France; 2Institut Curie, RPPA plateform, Paris, France; 3Former AstraZeneca, Macclesfield, United Kingdom
Visualisez l'afficheCirculating endothelial progenitor cell levels predict survival benefit in metastatic renal cell cancer patients treated with antiangiogenic agentsFrançoise Farace1,2, Marine Gross-Goupil3, Elodie Tournay4, Melissa Taylor1,2, Catherine Hill4, Bernard Escudier31 Translational Research Laboratory - 2 University of Paris-Sud, INSERM U981 - 3 Department of Medecine - 4 Department of Biostatistics, Institut Gustave Roussy
Visualisez l'affichePotential tumor suppressor role of PHD2 : functional study of mutations identified in patients with congenital polycythemia with or without paragangliomaCharline Ladroue1, Romain Carcenac1, Sophie Gad1, Michel Barrois2, Michel Leporrier3, Nicole Casadevall4, Olivier Hermine5, Jean-Jacques Kiladjian6, André Baruchel7, Nathalie Mazure8, Jacques Pouyssegur8, Brigitte Bressac2, Jean Feunteun9, Stéphane Richard1,10, Betty Gardie11- Génétique Oncologique EPHE, INSERM U753, Institut de CancérologieGustave Roussy, Villejuif et Faculté de Médecine Paris-Sud, Le Kremlin-Bicêtre, France. gardie-capdeville@igr.fr
2- Service de Génétique, Institut de cancérologie Gustave Roussy,Villejuif, France
3- Service d’Hématologie Clinique, Centre Hospitalier Universitaire,Caen, France
4- Hôpital Saint Antoine, Assistance Publique–Hôpitaux de Paris andPierre et Marie Curie University, Institut Gustave Roussy, Inserm, UMR790, Villejuif, France
5- Service d’Hématologie, Hôpital Necker-Enfants Malades, AP-HP, Paris, France
6- Service d’Hématologie, Hôpital Avicenne, AP-HP, Bobigny, France
7- Service d’Hématologie, Hôpital St. Louis, Paris, France
8- Institut de biologie du développement et cancer, CNRS UMR-6543,Université de Nice, France
9- Institut de cancérologie Gustave Roussy, CNRS-UMR8200, Villejuif,France
10- Centre de Référence Cancers rares INCa “PREDIR”, Service d'Urologie, CHU, Le Kremlin-Bicêtre et Service de Néphrologie, Hôpital Necker, Paris, France.
Visualisez l'afficheIntratumoral heterogeneity of HER2/neu expression in diffuse-gastric carcinoma of European patients and its relevance for patients' managementGorana Tomasic1, Gabriel G. Malouf1, Virginie Marty1, David Malka2, Philippe Vielh1, Michel Ducreux2 and Valerie Boige21 Department of pathology; 2 Department of medicine, Institut Gustave Roussy, Villejuif, France
Visualisez l'afficheThe prognostic impact of epithelial mesenchymal transition markers in primary diffuse gastric carcinomaand their relative lymph nodesGabriel G. Malouf 2, Gorana Tomasic 1, Virginie Marty 1, Dominique Elias 3, David Malka 2, Michel Ducreux 2 and Valérie Boige 21 Department of pathology; 2 Department of medicine; 3 Department of surgery; Institut Gustave Roussy, Villejuif, France
Visualisez l'affichePrognostic value of circulating endothelial and progenitor cells in advanced cancer patients enrolled in phase 1 in association with clinical prognostic scores Christophe Massard, Marie-Cecile Le Deley, Carlos Gomez Roca, Isabelle Borget, Jean-Charles Soria, Françoise FaraceUniversité Paris XI, SITEP (Service des Innovations Thérapeutiques Précoces), Département de Médecine, Institut Gustave Roussy, Villejuif, France
Visualisez l'afficheRestoration of p53 function in soft tissue sarcomas correlates with increased sensitivity to TNF-?Izabela Stasik PhD1, Jane Muret MD1,2, Abdelali Jalil PhD1, Philippe Terrier MD3, Axel Lecesne MD4, Sylvie Bonvalot MD, PhD1,5 and Salem Chouaib1INSERM U7531, Anesthesia2, Pathology3, Medical oncology4, Surgical oncology5
departments, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
Visualisez l'afficheC7,C9-DIMETHYL-IFOSFAMIDE ANALOGS EVALUATION FOR ANTITUMOR ACTIVITY AND TOXICITY detoxification pathways hypothesis for nephrotoxicity explanationB. GIRAUD, G. HÉBERT, A. DEROUSSENT, E. DAUDIGEOS, S. MARTELLI, G. VASSAL, A. PACI.Pharmacology and new treatments of cancer, UPRES EA3535, Paris XI University, Integrated Research Cancer Institute, Institut de cancérologie Gustave Roussy, Villejuif, France
Visualisez l'affichePhase I trials of molecularly targeted agents: evaluating cumulative toxicitySophie Postel-Vinay 1,2, Carlos Gomez-Roca1, Rhoda Molife2, Bhavesh Anghan2, Jean-Charles Soria1, Stan Kaye2 and Xavier Paoletti31 Institut Gustave Roussy, 39 rue Camille Desmoulins, 94800 Villejuif, France
2 Drug Development Unit, The Royal Marsden Hospital NHS Fundation Trust, The Institute of Cancer Research, Downs Road, Sutton Surrey, SM2 5PT United Kingdom
3 Institut Curie, 26 rue d’Ulm, 75005 Paris, France
Visualisez l'affiche
ASCO 2010 - 4-8 juin 2010 - Chicago - EU
Complete Remission with TKI in Renal Cell Carcinoma : experience in 65 patients from the French Kidney Cancer GroupL. Albiges(1), S. Oudard(2), S. Negrier(3), A. Caty(4), G. Gravis(5), F. Joly(6), B. Duclos(7), L. Geoffrois(8), F. Roland(9), B. Escudier(1)*(1) Institut Gustave Roussy, Villejuif: (2) Hôpital Européen Georges Pompidou, Paris; (3) Centre Léon Bérard, Lyon;(4) Centre Oscar Lombret, Lille; (5) Institut Paoli Calmette, Marseille; (6) Centre François Baclesse, Caen;
(7) Centre Hospitalier Universitaire, Strasbourg ; (8) Centre Alexis Vautrin, Nancy; (9) Centre René Gauducheau, Nantes; France. * On behalf of the members of the Groupe Français d’Immunothérapie.
Visualisez l'afficheMyxovirus resistance 1 (MX1) expression predicts efficacy of anthracycline?based chemotherapy in early breast cancer.F Andre1, M Delorenzi 2, A Goubar1, M Lacroix?triki 3, N Berrada1, C Desmedt 4, C. Sotiriou4, J De La Cruz 1, V Scott 1,R Conforti 5, D Khayat 5, W. F Symmans 6, G N. Hortobagyi7, S Delaloge1, L Pusztai7.1 INSERM U981, Institut Gustave Roussy, Villejuif 2 NCCR Molecular Oncology, ISREC, School of Life Sciences, EPFL, Lausanne, Switzerland 3. Department of Pathology, Centre Claudius Regault, Toulouse, France 4 . Medical Oncology Department, Jules Bordet Institute; Brussels, Belgium 5.
Department of Medical Oncology, Hôpital Pitie Salpetriere, Paris, France 6. Department of Breast Pathology and 7. medical oncology, The University of Texas, M. D. Anderson Cancer Center, Houston, TX
Visualisez l'afficheHigh throughput technologies to personalize medical treatment in patients with metastatic breast cancerR Wolp-Diniz1, J De La Cruz1, V Scott1, C Richon1, P Dessen1, L Lacroix1, S Delaloge1, M Campone2, MC Mathieu1, T Bachelot3, F Dalenc4, V Lazar1, F Andre1.1 INSERM U981, Institut Gustave Roussy, Villejuif, France. 2 Centre René Gauducheau, Nantes, France. 3 Centre Léon Bérard, Lyon, France. 4 Centre Claudius Regault, Toulouse, France.
Visualisez l'afficheQuality of surgical margins and local recurrence in primary extremity soft tissue sarcoma: size is not enoughBonvalot Sylvie (1), Dunant Ariane (2), Le Péchoux Cécile (3), Terrier Philippe (4), Rimareix Françoise (1), Boulet Bérénice (5), Mejdoub Leila (6), Cioffi Angela (7), Domont Julien (7), Le Cesne Axel (7)Institut Gustave Roussy, Villejuif, France
(1) Surgery, (2) Statistics, (3) Radiotherapy, (4) Pathology, (5) Radiology, (6) Data management, (7) Medical oncology
Visualisez l'afficheTwenty-years results of alternating radiotherapy and chemotherapy in non-metastatic inflammatory breast cancer.E. Lima Pessoa (1,2), A. Dunant (1), S. Heymann (1), S. Delaloge (1), M. Spielmann (1), C. Uzan (1), M.C. Mathieu (1), R. Arriagada (1), H. Marsiglia (1,3), C. Bourgier (1)1. Institut Gustave Roussy – France; 2. Hospital do Servidor Estadual de São Paulo - Brazil; 3. University of Florence – Italy
Visualisez l'affichePre-operative concomitant chemo-radiotherapy in chemotherapy-refractory breast cancer enables to perform curative surgery and improves pathological tumor response.I. Ghorbel, S. Heymann, S. Delaloge, A. Belaid, F. Azoury, C. Mazouni, C. Balleyguier, P. Vielh, H. Marsiglia, C. Bourgier Institut Gustave Roussy
Visualisez l'affichePilot program of fast-track germline genetic analyses as part of integrated breast, ovarian, or gatrointestinal personalized cancer care programO. Caron1, B. Bressac-de-Paillerets1, D. Malka1, A. Remenieras1, C. Bourgier1, C. Uzan1, M. Spielmann1, M. Blayau2, T. Frébourg3, S. Delaloge11: Institut Gustave Roussy, Villejuif; 2: CHU, Rennes,
3: CHU Rouen - France
Visualisez l'afficheRisk factors of altered well-being after prophylactic salpingo-oophorectomy among women at increased risk of hereditary ovarian cancerC.Touboul, C.Uzan, J.L.Ichante, O.Caron, A.Dunant, S.Dauchy, S.Gouy, M.Spielmann, P.Morice, S.DelalogeInstitut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
Visualisez l'afficheOutcome of colorectal liver metastases vanishing under chemotherapy and finally missing after surgery Gaujoux S, Goèré D, Deschamp F, Souadka A, Dumont F, Boige V, Malka D, de Baere Th, Dromain C, Ducreux M, Elias DInstitut Gustave Roussy, 39 Rue Camille Desmoulins, 94805 Villejuif, France
Visualisez l'afficheAn international pooled analysis identifying predictive factors associated with toxicities in Phase I trials (Delphi)C. Gomez-Roca (1), C. Baey (2), D. Olmos (3), A. Berens (5), E. Bigger (4), P. LoRusso (5), M. Rothenberg (4), S.Kaye (3), JP Pignon (2), JC Soria (1)1SITEP, Department of Medecine, Institut Gustave Roussy; 2Unité de méta-analyse, Service de Biostatistique et
d’Epidémiologie, Institut Gustave Roussy; 3Drug Development Unit, Royal Marsden Hospital and Institut of Cancer Research;
4Phase 1 Unit, Vanderbilt-Ingram Cancer Center; 5Phase 1 Unit, Karmanos Cancer Center
Visualisez l'afficheHepatic Arterial Infusion (HAI) of Oxaliplatin plus Intravenous (iv) Fluorouracil (FU), Leucovorin (LV) and Cetuximab for First-Line Treatment of Unresectable Colorectal Liver Metastases (CRLM) (CHOICE): A Multicenter Phase 2 StudyDavid Malka1, Emmanuelle Paris1, Caroline Caramella1, Eveline Boucher2, Rosine Guimbaud3, Aljosa Celebic1, Thierry De Baere1, Dominique Elias1, Jean-Pierre Pignon1, Michel Ducreux11 Institut Gustave Roussy (Villejuif), 2 Centre Eugène Marquis (Rennes), 3 CHU Purpan (Toulouse) – France
Visualisez l'affichePhase I trials of molecularly targeted agents: should we pay more attention to late toxicities?Sophie Postel-Vinay 1,2, Carlos Gomez-Roca1, Rhoda Molife2, Bhavesh Anghan2, Jean-Charles Soria1, Stan Kaye2 and Xavier Paoletti31 Institut Gustave Roussy, 39 rue Camille Desmoulins, 94800 Villejuif, France
2 Drug Development Unit, The Royal Marsden Hospital NHS Fundation Trust and The Institute of Cancer Research Downs Road, Sutton Surrey, SM2 5PT, United Kingdom
3 Institut Curie, 26 rue d’Ulm, 75005 Paris, France
Visualisez l'affichePhase I/II trial of association of sorafenib in combination with temozolomide in patients with metastatic melanoma. Looking for predictive markers of efficacy.C Robert1, N Chaput2, N Lassau3, A Auperin4, S Koscielny4, E Hollville1, V Lazar5, L Lacroix5, JC Soria6, C Mateus1 Gustave Roussy Institute, Villejuif, France - Departments of :1: Dermatology, 2: Immunology, 3: Imaging, 4: Biostatistics, 5: Translational Research, 6: Medicine.
Visualisez l'afficheActivation of the MAP-kinase pathway in the skin of patients treated with sorafenib; Clinical and molecular characterization of skin tumors associated with the multikinase inhibitor sorafenib C Mateus, JP Arnault, G Tomasic, J Wechsler, A Eychenne,
L Lacroix, E Hollville, B Escudier, JC Soria, C RobertGustave Roussy Institute, Villejuif, France Departments of : Dermatology, Pathology, Translational Research, Medicine. & Curie Institute, Paris, France
Visualisez l'affichePROGNOSTIC FACTORS OF A LARGE RETROSPECTIVE SERIES OF MUCINOUS BORDERLINE TUMORS OF THE OVARYMartin Koskas, Catherine Uzan, Sebastien Gouy, Patricia Pautier, Catherine Lhommé, Christine Haie-Meder, Pierre Duvillard, Philippe MoriceInstitut Gustave Roussy, Villejuif, France
Visualisez l'affiche
French multicentric prospective study of dynamic contrast-enhanced ultrasound (DCE-US) for the evaluation of antiangiogenic treatments in 400 patients
N. Lassau *, MD, PhD, J. Lacroix, MD, S. Taieb, MD, R. Aziza, MD, V. Vilgrain, MD, PhD, M. Cuinet, MD, A. Sarran, MD, C. Labbe, MD, J.P Armand, MD, S. Koscielny, PhD*Institut Gustave Roussy, Ultrasonography Unit, Imaging department, UMR8081-IR4M, Villejuif; Centre François Baclesse, Caen; Centre Oscar Lambret, Lille; Centre Claudius Regaud, Toulouse;
CHU de Beaujon, Clichy; Centre Léon Bérard, Lyon; Institut Paoli Calmettes, Marseille; Centre René Gauducheau, Nantes; Institut Claudius Regaud, Toulouse, FRANCE
